Dr. David F. Mobley, MD

Dr. Mobley practices at Texas Children's Hospital - Mfm the Methodist Hospital - HOPD in Houston, Texas.

Dr. Mobley's NPI, 1649272170, was assigned on August 15, 2005. Dr. Mobley graduated from University of Tennessee Health Science Center College of Medicine - Memphis in 1968. Dr. Mobley holds Texas license D6666.

Dr. Mobley's primary practice is Texas Children's Hospital - Mfm the Methodist Hospital - HOPD, at 6550 Fannin St, Houston, TX 77030.

Dr. Mobley's primary practice is Texas Children's Hospital - Mfm the Methodist Hospital - HOPD in Houston, Texas. Dr. Mobley is also affiliated with Houston Methodist Hospital. The medical group on file is Houston Methodist Specialty Physician Group. Dmand AI also links Dr. Mobley to 4 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mobley practices, 8 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Mobley's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Mobley is board certified in urology by the American Board of Urology. Dmand AI has Dr. Mobley's licenses on file in 4 states: Texas, California, Arkansas and Tennessee.

Dmand AI lists bladder disease, enlarged prostate, enlarged prostate transurethral surgery (TURP), erectile dysfunction, kidney stone disease, testicular dysfunction, urinary endoscopy and urine flow blockage among the conditions Dr. Mobley treats.

CMS data shows 1,512 Medicare services from Dr. Mobley across 10 procedure codes in 2024, for 787 Medicare patients. Medicare paid $87,860 for them. Every service was in an office.

CMS counts 787 Medicare patients who saw Dr. Mobley in 2024. The largest group is 65 to 74, with 357 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 1.09, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Mobley's median patient age at 72, with 10% women.

In 2024, Dr. Mobley wrote 4,032 Medicare Part D claims for 962 patients. 94% of them were for generic drugs. CMS names the drug for 3,895 of them, across 28 drugs with 11 or more claims each, at $665,890 in total drug cost. In 2023, CMS named 3,739 claims across 29 drugs.

Dr. Mobley accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Mobley as offering telehealth.

Prostate resection: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 23 papers to Dr. Mobley, published from 2015 to 2017. The most frequent topics are Prostatic Hyperplasia, Erectile Dysfunction and Penile Prosthesis. Dr. Mobley has published most often in Urology. Dr. Mobley's most frequent co-authors are Daniel R. Saltzstein, MD, Rodney Udell Anderson, MD and Ashley R. Beattie, MD.

Dmand AI links Dr. Mobley to 1 clinical trial. Conditions studied include Prostatic Hyperplasia and Prostatic Diseases.

CMS Open Payments shows 520 general payments to Dr. Mobley from 59 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 50% of the total. Astellas Pharma US Inc paid the most, $39,169. It also lists 10 research payments totaling $977 in 2019.

Dmand AI lists 1 award for Dr. Mobley.

Dr. Mobley graduated from University of Tennessee Health Science Center College of Medicine - Memphis in 1968. Dr. Mobley is a member of ACS.

Dr. Mobley is in network with 18 carriers, including Elevance, Aetna and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.